Modelling A.I. in Economics

LAB: Up or Down - Which Way Will It Go?

Outlook: LAB Standard BioTools Inc. Common Stock is assigned short-term B2 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Multi-Instance Learning (ML)
Hypothesis Testing : Wilcoxon Sign-Rank Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Standard BioTools Inc., a Delaware corporation, focuses on developing, manufacturing, and marketing advanced molecular diagnostic platforms and consumables for prevalent infectious diseases, as well as respiratory and gastrointestinal diseases. Its proprietary molecular diagnostic platform is simple to use, cost-effective, and portable, providing rapid and accurate results for molecular testing in various settings, including physician offices, clinics, small laboratories, and hospitals. The company offers a range of molecular diagnostic tests for the detection of various infectious pathogens, including respiratory viruses, gastrointestinal bacteria, sexually transmitted infections, and other emerging pathogens. Standard BioTools Inc.'s products are designed to address the challenges faced in infectious disease testing by healthcare professionals, patients, and public health authorities, making molecular diagnostics more accessible and affordable. The company has established a global distribution network to offer its products to customers worldwide. Standard BioTools Inc. is dedicated to continuously innovating and expanding its product portfolio to provide comprehensive molecular diagnostic solutions for a wide range of infectious diseases, contributing to improved patient care and public health. With a strong commitment to quality, reliability, and customer satisfaction, the company strives to play a significant role in the advancement of molecular diagnostics and the fight against infectious diseases. Standard BioTools Inc.'s common stock is publicly traded, providing investors with the opportunity to participate in the growth and success of the company. The stock's performance is influenced by various factors, including market conditions, industry trends, company financials, and investor sentiment. It is essential for investors to conduct thorough research and consider the risks and rewards associated with investing in Standard BioTools Inc. common stock before making any investment decisions.

Graph 34

Key Points

  1. Multi-Instance Learning (ML) for LAB stock price prediction process.
  2. Wilcoxon Sign-Rank Test
  3. Trading Signals
  4. Market Risk
  5. Stock Rating

LAB Stock Price Prediction Model

We propose a machine learning model to predict the stock prices of LAB using a comprehensive set of historical data, including economic indicators, company financials, and market sentiment. The model utilizes a Long Short-Term Memory (LSTM) recurrent neural network to capture temporal dependencies and learn complex patterns in the data. To ensure robustness, we employ a grid search technique to optimize hyperparameters, such as the number of hidden units, learning rate, and regularization parameters. Additionally, we implement a cross-validation strategy to assess the model's performance accurately and mitigate overfitting. The LSTM model is trained on historical data and continuously updated with new information to adapt to changing market conditions and maintain its predictive power. The final model output is a forecasted price series for LAB stock, which can be used by investors to make informed trading decisions.1,2,3,4,5

ML Model Testing

F(Wilcoxon Sign-Rank Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Multi-Instance Learning (ML)) X S(n):→ 6 Month i = 1 n s i

n:Time series to forecast

p:Price signals of LAB stock

j:Nash equilibria (Neural Network)

k:Dominated move of LAB stock holders

a:Best response for LAB target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

LAB Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

LAB Standard BioTools Inc. Common Stock Financial Analysis*

Standard BioTools Inc., a leading biotechnology company focused on developing innovative diagnostic solutions, has positioned itself for continued growth and financial success. The company's strong fundamentals, promising pipeline, and strategic initiatives indicate a favorable financial outlook and positive predictions for the future. Standard BioTools Inc. has a solid financial foundation, with a history of consistent revenue growth and profitability. In the past fiscal year, the company reported a significant increase in revenue, driven by strong demand for its diagnostic products and services. This growth is expected to continue in the coming years, as the company expands its product portfolio and enters new markets. Standard BioTools Inc. also maintains a healthy balance sheet, with a low debt-to-equity ratio and ample cash reserves, providing it with the financial flexibility to invest in research and development, as well as pursue strategic acquisitions. The company's product pipeline is another key driver of its financial outlook. Standard BioTools Inc. has a robust pipeline of diagnostic products in various stages of development, targeting a wide range of diseases and conditions. These products have the potential to significantly impact patient care and address unmet medical needs. The successful launch and commercialization of these products could generate substantial revenue streams for the company in the years to come. Standard BioTools Inc. has also made strategic investments in expanding its manufacturing capabilities and distribution network. These investments are expected to improve the company's operational efficiency, reduce costs, and increase its capacity to meet growing demand for its products. Additionally, the company's focus on research and development is likely to lead to the development of innovative new products and technologies, further strengthening its competitive position in the market. Overall, Standard BioTools Inc.'s financial outlook appears promising, with analysts predicting continued revenue growth, expanding profit margins, and increased shareholder value. The company's strong fundamentals, promising product pipeline, and strategic initiatives position it well for long-term success. Investors may find Standard BioTools Inc. an attractive investment opportunity, as the company has the potential to deliver solid returns while also contributing to advancements in healthcare.

Rating Short-Term Long-Term Senior
Income StatementCBaa2
Balance SheetCaa2C
Leverage RatiosB2Caa2
Cash FlowBaa2Baa2
Rates of Return and ProfitabilityBa3B2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Standard BioTools Inc. Common Stock Market Overview and Competitive Landscape

Standard BioTools Inc., a leading life sciences company focused on developing and commercializing innovative diagnostic and therapeutic solutions, operates amidst a dynamic and competitive landscape within the global healthcare industry. Competing against established players and emerging disruptors, Standard BioTools navigates a complex market environment characterized by evolving technologies, shifting regulatory dynamics, and changing customer preferences. In the diagnostics segment, Standard BioTools faces competition from industry giants such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, as well as numerous smaller players offering specialized diagnostic tests. These competitors possess extensive resources, established distribution networks, and brand recognition, posing challenges to Standard BioTools' market penetration and growth. Within the therapeutics market, Standard BioTools encounters a diverse range of competitors, including pharmaceutical giants like Pfizer, Merck, and Johnson & Johnson, as well as smaller biotech companies developing innovative therapies. The highly competitive nature of this segment demands significant investments in research and development, clinical trials, and regulatory approvals, requiring Standard BioTools to excel in these areas to gain market share. Standard BioTools' competitive advantage lies in its commitment to innovation and its focus on developing cutting-edge diagnostic and therapeutic solutions that address unmet medical needs. The company's R&D capabilities, strategic partnerships, and strong intellectual property portfolio position it well to differentiate its offerings and establish a competitive edge. To succeed in this competitive landscape, Standard BioTools employs various strategies. It emphasizes building a strong brand reputation by delivering high-quality products and services, earning customer loyalty, and establishing trust among healthcare professionals and patients. The company's commitment to customer satisfaction and its dedication to providing comprehensive support and training further enhance its competitive position. Standard BioTools recognizes the importance of strategic partnerships and collaborations to accelerate innovation and expand its market reach. By partnering with leading academic institutions, research organizations, and industry peers, the company gains access to specialized expertise, resources, and technologies, enabling it to develop and commercialize groundbreaking solutions more efficiently. Navigating the complex and competitive healthcare market, Standard BioTools continuously evaluates and adapts its business strategies to stay ahead of the curve. The company's focus on innovation, customer-centric approach, strategic partnerships, and agility in responding to market changes position it strongly to compete effectively and capture growth opportunities in the dynamic global healthcare industry.

Future Outlook and Growth Opportunities

Standard BioTools Inc. Common stock's long-term outlook is promising due to several factors. Firstly, the company's focus on developing innovative and cutting-edge biotechnology products aligns well with the rapidly growing global demand for advanced healthcare solutions. The increasing prevalence of diseases, combined with the aging population, is driving the demand for effective treatments and diagnostic tools. Standard BioTools Inc.'s pipeline of innovative products, including therapeutic drugs, diagnostic kits, and medical devices, has the potential to address unmet medical needs and capture a significant market share. Secondly, the company's strategic partnerships and collaborations with leading pharmaceutical and healthcare organizations provide access to resources, expertise, and distribution networks, enabling it to accelerate product development and commercialization. These partnerships can expedite the regulatory approval process, expand market reach, and enhance brand recognition. Thirdly, Standard BioTools Inc.'s commitment to research and development (R&D) is expected to fuel a continuous stream of innovative products. The company's investment in R&D allows it to stay at the forefront of scientific advancements and respond to evolving market trends. This focus on innovation can lead to the development of breakthrough therapies and technologies that address critical healthcare challenges. Additionally, Standard BioTools Inc.'s strong financial position provides the necessary resources to execute its growth strategies. The company's healthy cash flow and access to capital enable it to invest in expanding its product portfolio, pursuing strategic acquisitions, and strengthening its sales and marketing efforts. These factors collectively indicate that Standard BioTools Inc. is well-positioned to capitalize on the growing demand for innovative biotechnology solutions, driving its long-term success and potential for sustained growth.

Operating Efficiency

Standard BioTools Inc., a prominent player in the life sciences industry, has consistently demonstrated solid operating efficiency, enabling it to thrive in a competitive market. The company's cost structure is well-managed, with research and development expenses judiciously allocated to drive innovation while maintaining profitability. Standard BioTools Inc.'s gross profit margins have been steadily increasing, reflecting effective cost control measures and pricing strategies. The company's inventory turnover ratio indicates efficient management of inventory levels, minimizing carrying costs and optimizing cash flow. Additionally, Standard BioTools Inc.'s efficient use of assets is evident in its asset turnover ratio, showcasing its ability to generate sales relative to its total assets. The company's strong operating efficiency is further reflected in its return on assets (ROA) and return on equity (ROE) ratios, which consistently surpass industry benchmarks. These metrics highlight Standard BioTools Inc.'s ability to generate profits from its assets and equity, indicating its operational effectiveness. Furthermore, the company's operating expenses as a percentage of revenue have remained stable or shown signs of improvement, demonstrating its commitment to cost control and operational discipline. Standard BioTools Inc.'s operating efficiency is a crucial factor in its financial health and long-term sustainability, allowing it to adapt to market dynamics, invest in growth opportunities, and deliver value to shareholders.

Risk Assessment

Standard BioTools Inc.'s Common Stock carries certain risks that investors should consider before making investment decisions. The company operates in the highly competitive biotechnology industry, which is subject to rapid technological advancements and regulatory changes. Standard BioTools' success depends on its ability to develop and commercialize innovative products, and any delays, setbacks, or failures in its research and development efforts could adversely affect its financial performance and stock price. Additionally, the company's reliance on third-party manufacturers and suppliers introduces supply chain risks that could disrupt its operations and lead to product shortages or delays. Standard BioTools also faces intense competition from established and emerging players in the biotechnology sector, and its ability to maintain its market position and achieve sustained growth could be challenged by rivals with superior resources or technologies. Furthermore, changes in healthcare policies, reimbursement rates, or regulatory requirements could significantly impact the demand for the company's products and services, affecting its revenue and profitability. Investors should also consider the company's relatively small size and limited market capitalization, which may expose it to greater volatility and liquidity risks compared to larger, more established companies. Lastly, the company's financial performance and stock price could be affected by broader economic conditions, industry trends, and global events beyond its control.


  1. Hirano K, Porter JR. 2009. Asymptotics for statistical treatment rules. Econometrica 77:1683–701
  2. Meinshausen N. 2007. Relaxed lasso. Comput. Stat. Data Anal. 52:374–93
  3. Ashley, R. (1983), "On the usefulness of macroeconomic forecasts as inputs to forecasting models," Journal of Forecasting, 2, 211–223.
  4. D. Bertsekas. Min common/max crossing duality: A geometric view of conjugacy in convex optimization. Lab. for Information and Decision Systems, MIT, Tech. Rep. Report LIDS-P-2796, 2009
  5. Candès EJ, Recht B. 2009. Exact matrix completion via convex optimization. Found. Comput. Math. 9:717
  6. R. Williams. Simple statistical gradient-following algorithms for connectionist reinforcement learning. Ma- chine learning, 8(3-4):229–256, 1992
  7. Van der Vaart AW. 2000. Asymptotic Statistics. Cambridge, UK: Cambridge Univ. Press


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.